Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 14, 2013; 19(34): 5645-5650
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5645
Quality of compounded topical 2% diltiazem hydrochloride formulations for anal fissure
Monil Shah, Laura Sandler, Vishwas Rai, Charu Sharma, Lakshmi Raghavan
Monil Shah, Laura Sandler, Ventrus Biosciences, Inc., New York, NY 10013, United States
Vishwas Rai, Charu Sharma, Lakshmi Raghavan, DermPathe Pharmaceuticals, Branchburg, NJ 08876, United States
Author contributions: Shah M, Sandler L, Rai V, Sharma C and Raghavan L contributed to conception, design, acquisition of data, analysis and interpretation of data, drafting the manuscript, revising it critically for important intellectual content, and final approval of the version to be published.
Supported by Ventrus Biosciences, Inc., New York, NY, United States
Correspondence to: Monil Shah, PharmD, MBA, Ventrus Biosciences, Inc., 99 Hudson Street, 5th Floor, New York, NY 10013, United States. mshah@ventrusbio.com
Telephone: +1-646-7065208 Fax: +1-646-7065101
Received: May 9, 2013
Revised: June 29, 2013
Accepted: August 4, 2013
Published online: September 14, 2013
Processing time: 126 Days and 12.1 Hours
Abstract

AIM: To investigate the quality of topical 2% diltiazem formulations extemporaneously compounded by retail pharmacies openly offering drug-compounding services.

METHODS: A participating healthcare professional wrote 12 prescriptions for compounded 2% diltiazem cream, with 2 refills allowed per prescription. The 12 sets of prescriptions were filled, at intervals of 1-2 wk between refills, at 12 different independent retail pharmacies that openly offer drug-compounding services in a major metropolitan region. The 36 resultant preparations, provided as jars or tubes, were shipped, as soon as each was filled, at ambient temperature to the study core laboratory for high-performance liquid chromatography (HPLC) analysis, within 10 d of receipt. For the HPLC analysis, 8 different samples of the topical diltiazem, each approximately 1 g in weight, were taken from prespecified locations within each container. To initiate the HPLC analysis, each sample was transferred to a 100 mL volumetric flask, to which methanol was added. The HPLC analysis was conducted in accordance with the laboratory-validated method for diltiazem in cream, ointment, and gel formulations. The main outcome measures were potency (percentage of label claim) and content uniformity of the compounded topical 2% diltiazem formulations.

RESULTS: Of the 36 prescriptions filled, 30 were packaged in jars and 6 were packaged as tubes. The prescriptions were specifically for cream formulations, but 6 of the 12 pharmacies compounded 2% diltiazem as an ointment; for another pharmacy, which had inadequate labeling, the dosage form was unknown. The United States Pharmacopoeia (USP) standard for potency is 90%-115% of label claim. Of the 36 preparations, 5 (13.89%) were suprapotent and 13 (36.11%) were subpotent. The suprapotent prescriptions ranged in potency from 117.2% to 128.5% of label claim, and the subpotent prescriptions ranged in potency from 34.8% to 89.8% of label claim. Fourteen (38.9%) preparations lacked content uniformity according to the USP standard of 90%-110% potency and < 6% relative standard deviation. Of the 30 formulations packaged in jars, 12 (40%) lacked content uniformity, while of the 6 formulations packaged in tubes, 2 (33.3%) lacked content uniformity. Nine of the 12 pharmacies (75%) failed USP potency or content-uniformity specifications for at least 1 of the 3 prescription fills. For 5 of the 12 pharmacies (41.7%), the mean potency across all three prescription fills was < 90% of label claim.

CONCLUSION: Patients prescribed topical 2% diltiazem for treatment of anal fissure frequently receive compounded formulations that are misbranded with respect to potency and that lack content uniformity.

Keywords: Anal fissure; Pharmacy compounding; Topical diltiazem; Formulation potency; Content uniformity

Core tip: The use of topical 2% diltiazem hydrochloride for treating anal fissures is supported by multiple clinical trials and is recommended in published practice parameters. As no commercially manufactured formulation of topical 2% diltiazem has been approved yet by the Food and Drug Administration for the treatment of anal fissure, prescriptions for the medication need to be extemporaneously compounded by retail pharmacies. Employing high-performance liquid chromatography analysis of topical 2% diltiazem formulations compounded by a sampling of pharmacies, we found a notable trend toward lack of content uniformity and misbranding of potency, suggesting that many patients might not receive the anticipated relief of anal-fissure pain.